8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

^{______________}

FORM 8-K

^{______________}

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 19, 2009

^{______________}

Stellar Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

^{______________}

Ontario, Canada	0-31198	Not Applicable
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

544 Egerton Street, London, Ontario, Canada, N5W 3Z8

(Address of Principal Executive Office) (Zip Code)

(519) 434-1540

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01

Regulation FD Disclosure

See Exhibit 99.1

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.	Description
99.1	Stellar Pharmaceuticals Provides Guidance for 2009 Second Quarter Revenues in Excess of One Million Dollars (CDN)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

STELLAR PHARMACEUTICALS INC.
By:	/s/ PETER RIEHL
	Peter Riehl President and Chief Executive Officer

Date:  June 19, 2009

EX-99.1

Exhibit 99.1

Press Release Source: Stellar Pharmaceuticals Inc.

STELLAR PHARMACEUTICALS PROVIDES GUIDANCE

FOR 2009 SECOND QUARTER REVENUES

IN EXCESS OF ONE MILLION DOLLARS (CDN)

London, Ontario - June 19, 2009 – Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB:SLXCF) a Canadian pharmaceutical developer and marketer of high quality, cost effective products for select health care markets, today announced that its second quarter revenues will exceed one million dollars, an increase of approximately 55% over revenues reported for the same quarter in 2008 and the Company also expects that it will be profitable for the period.

Peter Riehl, Stellar’s President and CEO, stated, “This is the strongest second quarter in the Company’s history, with revenues up substantially in all markets.  The Company expects to also be profitable for the period, making this the third consecutive quarter that the Company has shown a profit.  We are very pleased to see this growth given the challenging economic times.”

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology:  NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome an inflammatory disease of the urinary bladder wall.  Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

For More Information Please Contact:

Stellar Pharmaceuticals Inc.		Arnold Tenney
Peter Riehl	or	(416) 587-3200
President & CEO
(800) 639-0643 or (519) 434-1540
email: Corpinfo@StellarPharma.com